expressed genes, for example, RARRES3, CTGF and CRABP2, were not only associated with disease progression but are also part of the retinoic acid signaling pathway. We therefore speculated that retinoic acid treatment may represent a novel therapeutic approach in advanced tumors. Expression of these previously identified retinoic acid-regulated genes that are deregulated in advanced Wilms tumors should then be reversed after treatment with retinoic acid. Additionally, we aimed at the identification of novel retinoic acid-dependent genes in Wilms tumors through expression profiling of treated cells (See Supplementary Material).
All-trans retinoic acid (ATRA) is a vitamin A derivative capable of inhibiting cell proliferation and inducing cell differentiation (Ross et al., 2000) . These regulatory effects have been demonstrated in normal cells as well as in several types of cancer cells. A direct consequence of these experimental data has been the use of ATRA in the induction treatment of acute promyelocytic leukemia leading to high rates of complete remission and cure in combination with chemotherapy (for a review see Freemantle et al., 2003) . In several other cancer types, clinical trials with retinoic acid are currently performed, for example, in advanced neuroblastoma (Reynolds et al., 2003) .
To investigate the response of Wilms tumors to ATRA, we used two different sources of Wilms tumor cells: (1) MZ 128 are derived from a tumor with predominantly stromal histology, a WT1 mutation, and a cytogenetically detectable de novo chromosome 7/12 translocation (Lobbert et al., 1998) ; (2) WS 427 are primary cells from a triphasic tumor without WT1 mutation, where the majority of cells grew in a cobblestone-like pattern during short-term culture. Both types of cells were initially treated with different concentrations of ATRA (100 nM, 10 mM and 1 mM) for 24 h. Gene expression was then assayed by real-time qPCR for a series of RA-regulated genes, especially ones that had shown differential regulation in advanced Wilms tumors in our previous microarray study. Altogether 11 genes were studied by qPCR: RARRES1, RARRES3, CRABP2, IGFBP3, RARB, RARG and TRIM22 were upregulated by ATRA treatment, whereas ENPP2 was downregulated. RARRES2, IGF2
and RARA remained unchanged. The latter three genes also remained unchanged in advanced Wilms tumors. Data for six of these genes are shown in Figure 1 . It is important to note that differential gene expression occurred concordantly in both types of cells. ATRA concentrations of 100 nM had little effect, whereas 10 mM and 1 mM strongly altered gene regulation. Compared to 10 mM, application of 1 mM ATRA did not further enhance differential gene regulation.
To investigate how cell growth is influenced by continuous ATRA treatment, we additionally exposed both types of cells to ATRA for 5 days. The ATRAcontaining medium was changed once in between. Whereas cell growth was almost unchanged at a concentration of 100 nM ATRA as compared to untreated cells, higher concentrations markedly inhibited cell proliferation. Cell growth was completely stopped when a concentration of 1 mM ATRA was applied for 5 days (data not shown).
To assess global gene expression changes and to identify additional retinoic acid-regulated candidate genes in Wilms tumors, we performed microarray analysis of both cell lines after 24 h ATRA treatment. In these experiments, an ATRA concentration of 10 mM was chosen for two reasons: firstly, it exerted a strong regulatory effect in qPCR (compare Figure 1) , and secondly, previous experiments suggested similar concentrations to be effective in vivo (Reynolds et al., 1991) . For quality control, each experiment was performed as sandwich hybridization, that is, instead of a coverslip, a second microarray slide was used. The mean log-ratios M were calculated from replicates. Only gene replicates with optimal reproducibility, that is, difference of less than 75% of the calculated average log-ratio and signal intensity that was higher than background intensity were included in the final analysis.
For both types of cells, the 30 candidate genes with highest fold changes due to ATRA treatment are listed in Table 1 . Several of the genes identified are known ATRA targets, for example, IGFBP3 and CTGF/ IGFBP8 (Freemantle et al., 2002) , and their regulation was in accordance with the literature. All overlapping genes were concordantly regulated, that is, in the same direction.
We then performed hierarchical clustering of those genes that (1) were differentially regulated in advanced tumors and (2) changed their expression in ATRAtreated tumor cells. Hierarchical clustering of these genes revealed a frequent coregulation in individual tumors from our previous study, despite the heterogeneity of that collection (Figure 2) . Additionally, most genes exhibited opposite regulation after ATRA treatment as compared to their overall regulation in high risk and relapsed Wilms tumors. For example, the genes RARRES1 and RARRES3 had been frequently downregulated in high-risk and relapsed tumors, whereas their expression was increased after ATRA treatment. This ATRA-induced inverse expression of genes associated with disease progression is an important finding since it represents the first molecular evidence of a Figure 1 Examples of differential gene expression in both types of Wilms tumor cells after exposure to various concentrations of ATRA (Sigma, Taufkirchen, Germany) for 24 h. After RNA extraction with Trizol Reagent (Invitrogen, Karlsruhe, Germany), cDNA synthesis and real-time PCR were performed as described previously (Zirn et al., 2005) . qPCR fold changes refer to untreated control cells (fold change ¼ 1). Four genes were induced by ATRA (RARRES1, RARRES3, CRABP2, IGFBP3), whereas ENPP2/ATX represents an example of a downregulated gene. RARRES2 is not differentially regulated in a consistent manner cDNA microarray experiments were performed as sandwich hybridizations and standardized as described previously (Zirn et al., 2005) . To compare expression profiles, the difference of the mean log 2-ratios between ATRA-treated cells and control was calculated, respectively, based on replicated measurements
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Retinoid signaling
The retinoid signal is transduced by two families of nuclear receptors, the retinoic acid receptors (RARs) (RARA, RARB and RARG) and the retinoid X receptors (RXRA, RXRB and RXRG), which cooperate as RAR/RXR heterodimers (Kastner et al., 1997) . ATRA exclusively activates RARs, whereas 9-cis RA stimulates both RARs and RXRs. The upregulation of the RARs by ATRA has been described previously (Farias et al., 2002; Reynolds et al., 2003) . As a consequence of ATRA exposure in Wilms tumor cells, we found the RARs RARB and RARG to be upregulated (Table 1) , whereas RARA remained unchanged in both types of ATRA-treated Wilms tumor cells. RARB was represented in two different clones on the array, which were both independently upregulated in replicated measurements in both cell types. RARG was only upregulated in WS 427. Additionally, the RAR responders RARRES1 and RARRES3, which represent retinoid-inducible tumor suppressor genes, were induced by ATRA treatment.
For both genes, replicated gene expression measurements on the array resulted in strong upregulation in one cell type, but minor changes or poor reproducibility in the other (Figure 2 ). We therefore analysed both genes by real-time RT-PCR and found a strong and reproducible upregulation of both genes in both cell types (Figure 1) .
The expression of RARB, RARG, RARRES1 and RARRES3 strongly inhibits cellular proliferation and mediates differentiation of normal and cancer tissues. Correspondingly, RARB, RARRES1 and RARRES3 mRNA levels were found to be repressed in many different tumors (Freemantle et al., 2003; Shyu et al., 2003; Sriuranpong et al., 2004) . Moreover, downregulation of RARB and RARRES3 could be associated with disease progression in neuroblastoma (Cheung et al., 1998) and B-cell lymphocytic leukemia (Casanova et al., 2001) , respectively. In our previous microarray analysis of 77 Wilms tumors, RARRES1 and RARRES3 were also downregulated in advanced tumors. Therefore, we interpret the inverse expression of RARRES1 and RARRES3 following ATRA treatment as a positive response to ATRA. Together with RARB and RARG, these genes may be involved in differentiation processes in ATRA-treated Wilms tumor cells. During normal kidney development, retinoic acid is one of the Figure 2 Hierarchical clustering of several genes regulated by ATRA and associated with disease progression in our previous analysis of Wilms tumors (Zirn et al., in press ). Individual tumors are represented by vertical columns. High-risk and relapsed tumors are denoted by black squares in the middle bar. Gene symbols are listed on the right. The table below the red-green cluster lists the overall fold changes of these genes in high-risk (as opposed to intermediate risk) and relapsed (as opposed to 3-year relapse-free) tumors from our previous study. On the right side, the mean fold changes in both types of cells after ATRA treatment are displayed. In both, the microarray cluster and the table, green squares designate downregulation of a gene and red squares designate upregulation. Gray squares indicate missing or poorly reproducible data between replicated measurements Retinoic acid treatment of Wilms tumor cells B Zirn et al important factors involved in primary pattern formation and this may in part be recapitulated in these tumor cells (Burrow, 2000) .
DHRS3 (dehydrogenase/reductase SDR family member 3) also known as PSDR1 or retSDR1 (prostate and retinal short chain dehydrogenase/reductase) was also found to be strongly upregulated in both cell lines (13.6-and 4.6-fold). DHRS3 is a known retinoic acid-inducible gene (Cerignoli et al., 2002) that encodes a retinal reductase (Kedishvili et al., 2002) . Retinol regeneration by DHRS3 depends on the presence of the cellular retinoic acid binding protein CRABP2 (Cerignoli et al., 2002) , a gene that was concordantly upregulated in ATRA-treated Wilms tumor cells. In addition to classical RA signaling, further pathways appear to be affected by ATRA treatment that may mediate effects on growth control and differentiation as discussed below.
Smad/transforming growth factor-beta (TGFb) signaling
The activation of the TGFb pathway strongly inhibits cell cycle progression at the G1 phase with SMAD proteins as the principal intracellular transducers. Their capacity to activate TGFb target genes is enhanced by a direct interaction with RARG (Pendaries et al., 2003) . The upregulation of SMAD3 and RARG, which we found in ATRA-treated Wilms tumor cells, may contribute to enhanced TGFb signaling and may thereby counteract disease progression. This is consistent with the observation that inactivation of SMADs was associated with poor outcome in several cancer types, for example, breast and colorectal cancer (Xie et al., 2002; Xie et al., 2003) .
Interestingly, the ATRA-induced IGFBP6, IGFBP3 and CTGF/IGFBP8 genes are also thought to exhibit antiproliferative activities in vivo since upregulation, especially of the latter two, was inversely associated with tumor progression in several cancer types (Petridou et al., 2001; Xie et al., 2004) . These factors were further shown to mediate directly the antiproliferative and proapoptotic effects of TGFb (Kansra et al., 2000; Koliopanos et al., 2002) . Additionally, PDGF (platelet-derived growth factor) and plasminogen activators have been described as mediators of TGFb signaling (Battegay et al., 1990; Imai et al., 1997) . We found the receptors PDGFRA and uPAR (plasminogen activator urokinase receptor) to be upregulated in ATRA exposed Wilms tumor cells. Of note, overexpression of uPAR has been associated with longer survival in children with neuroblastoma (Li et al., 2004) . Taken together, this combination of differentially expressed genes strongly hints at a connection between retinoic acid and other signaling systems in tumor progression, of which the SMAD/TGFb pathway may play the most prominent role.
Genes involved in cell proliferation and matrix remodeling
Several genes differentially expressed as a consequence of ATRA exposure in Wilms tumors have previously described functions in cell proliferation: these are the upregulated genes DLC1, AKAP12/gravin and ITM2B, as well as the downregulated genes CKS2 and CCNA2. DLC1 and AKAP12/gravin were reported to be either deleted or downregulated in human cancer, whereas restoration of their expression induced apoptosis (Yuan et al., 2003; Choi et al., 2004) . ITM2B is a known regulator of cell death that promotes apoptosis and interacts with BCL2 (Fleischer et al., 2002) . Therefore, upregulation of these genes may contribute to growth inhibition in ATRA-treated Wilms tumor cells. CCNA2 and CKS2 are well-known cell cycle checkpoint genes whose overexpression was linked to cell proliferation and tumor progression (Urbanowicz-Kachnowicz et al., 1999; Bahnassy et al., 2004) . Hence, downregulation of these genes in Wilms tumors may convey antiproliferative effects.
The removal or modification of cell adhesion is a prerequisite of both tumor growth or spreading and tumor angiogenesis. Several integrins are involved in these processes and they not only mediate cellular adhesion to extracellular matrix proteins but also transduce intracellular signals that promote the attachment and migration of cells on the surrounding extracellular matrix (for a review see Jin and Varner, 2004) . We found the expression of ITGB1 (fibronectin receptor) and ITGA1 to be altered by ATRA. In addition, several components of the basement membrane that interact with integrins were differentially expressed after ATRA exposure, for example, laminin a4 (Gonzalez et al., 2002) , nidogen-2 (Salmivirta et al., 2002) and CTGF/IGFBP8 (Chang et al., 2004) . Therefore, matrix remodeling may also contribute to inhibition of cell growth in Wilms tumor cells.
Consequences for the potential clinical application of ATRA in advanced wilms tumors
The current study has identified a variety of regulatory genes that are candidate targets of ATRA in Wilms tumors. Several genes that had previously been associated with Wilms tumor progression were inversely regulated after ATRA treatment. This provides the first molecular evidence of a potential benefit of retinoic acid treatment in Wilms tumors. Especially in those tumors that resist conventional therapy, ATRA-induced growth inhibition may provide an alternative or additional therapeutic approach.
Further biological studies are clearly needed to confirm these positive effects of ATRA in Wilms tumors before first clinical trials with retinoids in advanced tumors could be envisaged. ATRA needs to be compared to other retinoids such as 13-cis RA and fenretinide that exhibit partially different pharmacological effects. Moreover, the mode of administration (continuous versus pulse therapy) influences pharmacokinetic properties and thereby impacts on the effectiveness of retinoid therapy. For example, in high-risk neuroblastoma, a phase III trial with high-dose pulse therapy significantly improved event-free survival (Reynolds et al., 2003) . Pulse therapy may be of advantage since continuous ATRA application was shown to induce its own metabolism, thus reducing peak levels of the drug (Adamson et al., 1997) .
Our study suggests that an ATRA concentration of 10 mM effectively inhibits cell growth and induces gene regulation. Drug levels between 1 and 10 mM were also reported to lead to growth inhibition in other in vitro studies in cancer cells and were suggested to be effectively reached in target tissues in vivo (Reynolds et al., 2003) . These are only some of the practical issues that would have to be addressed before retinoids could be clinically applied in advanced Wilms tumors, but our data suggest that it may be well worth the effort.
